The online version of this article (doi:10.1186/1475-2875-11-214) contains supplementary material, which is available to authorized users.
The authors declare no conflicts of interests.
Conceived study: NT, DL, JMC; collected data: NT; analysed data: all authors; drafted manuscript: NT; reviewed and edited manuscript all authors. All authors read and approved the final manuscript.
Relapsing Plasmodium vivax infection results in significant morbidity for the individual and is a key factor in transmission. Primaquine remains the only licensed drug for prevention of relapse. To minimize relapse rates, treatment guidelines have recently been revised to recommend an increased primaquine dose, aiming to achieve a cumulative dose of ≥6 mg/kg, i.e. ≥420 mg in a 70 kg patient. The aims of this study were to characterize the epidemiology of P. vivax infection imported into Queensland Australia, to determine the rates of relapse, to investigate the use of primaquine therapy, and its efficacy in the prevention of relapse.
A retrospective study was undertaken of laboratory confirmed P. vivax infection presenting to the two major tertiary hospitals in Queensland, Australia between January 1999 and January 2011.
Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown. The dose of primaquine prescribed to patients who subsequently relapsed that prescribed to patients who did not relapse.
Twenty relapses occurred following 151 primary episodes of P. vivax infection (13.2%). Relapses were confirmed among 3/21 (14.2%), 9/50 (18.0%), 1/54 (1.9%) and 7/18 (38.9%) of patients administered no dose, low dose, high dose and unknown primaquine dose respectively. High dose primaquine therapy was associated with a significantly lower rate of relapse compared to patients who were prescribed low dose therapy (OR 11.6, 95% CI 1.5-519, p = 0.005).
Relapse of P. vivax infection is more likely in patients who received low dose primaquine therapy. This study supports the recommendations that high dose primaquine therapy is necessary to minimize relapse of P. vivax malaria.
Queensland Notifiable Disease Report 1997–2001: Queensland Health Communicable Disease Unit. 112-116.
National Notifiable Diseases Surveillance Report 1–4: Australian Government Department of Helth and Ageing. 2011
Charles DM, Hart J, Davis WA, Sullivan E, Dowse GK, Davis TM: Notifications of imported malaria in Western Australia, 1990–2001: incidence, associated factors and chemoprophylaxis. Med J Aust. 2005, 182: 164-167. PubMed
Queensland Notifiable Disease Report 2002–2006: Queensland Health Communicable Disease Unit. 184-187.
Baird JK: A rare glimpse at the efficacy of primaquine. Am J Trop Med Hyg. 2007, 76: 201-202. PubMed
Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006, 75: 402-415. PubMed
Goller JL, Jolley D, Ringwald P, Biggs BA: Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg. 2007, 76: 203-207. PubMed
Duarte EC, Pang LW, Ribeiro LC, Fontes CJ: Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg. 2001, 65: 471-476. PubMed
Bottieau E, Clerinx J, Van Den Enden E, Van Esbroeck M, Colebunders R, Van Gompel A, Van Den Ende J: Imported non– Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg. 2006, 75: 133-138. PubMed
Galappaththy GN, Omari AA, Tharyan P: Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2007, 24 (1): CD004389-
Treatment of Malaria (Guidelines for Clinicians): Centre for Disease Control and Prevention. 2011
Therapeutic Guidelines Antibiotics. 2010, Therapeutic Guidelines, 14
Guidelines for the Treatment of Malaria. 2010, World Health Organisation, 2
Jelinek T, Nothdurft HD, Von Sonnenburg F, Loscher T: Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg. 1995, 52: 322-324. PubMed
Chiang TY, Lin WC, Kuo MC, Ji DD, Fang CT: Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. Clin Microbiol Infect. 2012, 10.1111/j.1469-0691.2012.03820.x. Epub ahead of print.
- Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study
James S McCarthy
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II